<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03094416</url>
  </required_header>
  <id_info>
    <org_study_id>13US-T404</org_study_id>
    <nct_id>NCT03094416</nct_id>
  </id_info>
  <brief_title>Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors</brief_title>
  <official_title>An Open-label Therapeutic Efficacy Study of Tirosint (Levothyroxine Sodium) Capsules in Thyroidectomized Patients Taking Proton Pump Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IBSA Institut Biochimique SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IBSA Institut Biochimique SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label therapeutic efficacy study of Tirosint (levothyroxine sodium) capsules&#xD;
      in thyroidectomized patients taking proton pump inhibitors and levothyroxine, evaluating&#xD;
      changes in serum levels of TSH upon switch to Tirosint with respect to baseline.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 30, 2018</start_date>
  <completion_date type="Actual">June 15, 2020</completion_date>
  <primary_completion_date type="Actual">June 15, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TSH (Thyroid Stimulating Hormone)</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>change in serum levels of TSH upon switch to levothyroxine sodium capsules with respect to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FT4 (free thyroxine)</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>change in serum levels of FT4 with respect to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TT4 (total thyroxine)</measure>
    <time_frame>12 weeks</time_frame>
    <description>change in serum levels of TT4 with respect to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FT3 (free triiodothyronine)</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>change in serum levels of FT3 with respect to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TT3 (total triiodothyronine)</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>change in serum levels of TT3 with respect to baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>CPK (creatine phosphokinase)</measure>
    <time_frame>12 weeks</time_frame>
    <description>changes in CPK towards baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>SHBG (sex hormone binding globulin)</measure>
    <time_frame>12 weeks</time_frame>
    <description>changes in SHBG towards baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>ferritin</measure>
    <time_frame>12 weeks</time_frame>
    <description>changes in ferritin towards baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>ACE (angiotensin converting enzyme)</measure>
    <time_frame>12 weeks</time_frame>
    <description>changes in ACE towards baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>lipid panel</measure>
    <time_frame>12 weeks</time_frame>
    <description>changes in lipid panel towards baseline</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Hypothyroidism;Postablative</condition>
  <arm_group>
    <arm_group_label>levothyroxine sodium capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>levothyroxine sodium capsules 88 to 250 mcg/day (depending on individual needs) for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levothyroxine sodium capsule</intervention_name>
    <description>after the run-in period, patients will be switched to levothyroxine sodium capsule at the same dose used during run-in</description>
    <arm_group_label>levothyroxine sodium capsules</arm_group_label>
    <other_name>Tirosint</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proton pump inhibitor</intervention_name>
    <description>for the whole study duration all subjects will keep taking their proton pump inhibitor medication, as per prescription and as before inclusion</description>
    <arm_group_label>levothyroxine sodium capsules</arm_group_label>
    <other_name>omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, rabeprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxine Sodium Tablets</intervention_name>
    <description>during the run-in period, subjects will continue taking their levothyroxine sodium tablet medication as per prescription and as before inclusion</description>
    <arm_group_label>levothyroxine sodium capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. written informed consent duly read, signed and dated by the subject;&#xD;
&#xD;
          2. aged ≥18 and ≤65 years;&#xD;
&#xD;
          3. history of hypothyroidism due to total thyroidectomy;&#xD;
&#xD;
          4. on stable LT4 doses for at least 6 weeks at screening (≥88 mcg daily and ≤250 mcg&#xD;
             daily);&#xD;
&#xD;
          5. TSH at screening ≥0.3 and ≤4.0 mIU/L;&#xD;
&#xD;
          6. history of gastroesophageal reflux disease or associated gastrointestinal issues on&#xD;
             prescription PPIs (i.e. omeprazole ≥20 mg daily, or esomeprazole ≥ 20 mg daily, or&#xD;
             lansoprazole ≥ 15 mg daily, or pantoprazole ≥ 40 mg daily) for at least 8 weeks before&#xD;
             screening visit and for whom chronic therapy with PPIs for the next 5 months has been&#xD;
             prescribed;&#xD;
&#xD;
          7. for women, adequate and continuative contraceptive measures until the end of the&#xD;
             study, if not in menopause;&#xD;
&#xD;
          8. reasonable assumption of understanding the study and willingness to take part to the&#xD;
             study and to comply with protocol requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. suspected or ascertained non-compliance with LT4 or PPI therapy;&#xD;
&#xD;
          2. subject requiring changes of levothyroxine dose;&#xD;
&#xD;
          3. use of over-the-counter (OTC) PPIs;&#xD;
&#xD;
          4. history of malabsorption or history of gastric bypass surgery, short-gut syndrome,&#xD;
             inflammatory bowel disease and other conditions of the gastrointestinal tract that may&#xD;
             affect drug absorption (e.g. celiac disease)3;&#xD;
&#xD;
          5. multiple co-morbidities (e.g. cardiac heart failure, active arrhythmia or history of&#xD;
             arrhythmia, particularly atrial fibrillation, uncompensated diabetes mellitus,&#xD;
             uncorrected adrenal insufficiency, seriously compromised hepatic, renal and/or&#xD;
             respiratory functions);&#xD;
&#xD;
          6. neoplastic pathology, active or in remission for less than 5 years (excluding the&#xD;
             basic thyroid pathology);&#xD;
&#xD;
          7. terminal condition;&#xD;
&#xD;
          8. parenteral or assisted enteral feeding;&#xD;
&#xD;
          9. presence of any medical condition or other circumstances which would significantly&#xD;
             affect the safety of the subject or decrease the chance of obtaining reliable data,&#xD;
             achieving study objectives or completing the study;&#xD;
&#xD;
         10. history of alcoholism, drug abuse or psychiatric diseases that could invalidate the&#xD;
             informed consent or limit the subject compliance with protocol requirements;&#xD;
&#xD;
         11. pregnant (positive urine pregnancy test at screening or baseline visits) or&#xD;
             breast-feeding subject or subject planning a pregnancy in the next months;&#xD;
&#xD;
         12. known hypersensitivity to the ingredients of the preparation involved in the study3;&#xD;
&#xD;
         13. use of forbidden concomitant medications;&#xD;
&#xD;
         14. regular consumption of soy and soy derivatives, cotton seed meals, walnuts, and&#xD;
             dietary fibres;&#xD;
&#xD;
         15. participation in other clinical studies during the 3 months prior to screening;&#xD;
&#xD;
         16. presumption of poor reliability/cooperation;&#xD;
&#xD;
         17. any reason which, in the opinion of the Investigator, would prevent the subject from&#xD;
             participating in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth D Burman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medstar Health Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Head and Neck Specialists</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Metabolic Research Centre</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2975</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Union Memorial Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYC Health + Hospitals/ Queens</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes &amp; Endocrinology Consultants, PC</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Ear Nose and Throat Clinic</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stonesifer Endocrine Care &amp; Clinical Research Inc., PS</name>
      <address>
        <city>Federal Way</city>
        <state>Washington</state>
        <zip>98003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 17, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2017</study_first_posted>
  <disposition_first_submitted>May 10, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>May 10, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 14, 2021</disposition_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypothyroidism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

